Your Guide to Better Health

Kisspeptin-10 women fertility ovulation: discover how this hypothalamic peptide controls the LH pulse behind ovulation, what clinical trials in IVF and PMOS show, and why it may be key to unexplained infertility. Research-driven, clinician-reviewed.

Semaglutide patent expiry biosimilar competition is arriving — but not equally everywhere. This explainer breaks down the US vs. global timeline, what the FDA's tentative generic approval means, why compounded semaglutide is no longer legal, and what cost-conscious GLP-1 users should do right now.

The RFK peptide policy 2026 shift is real. HHS Secretary Kennedy has directed the FDA to review 14 restricted peptides for compounding access — here's what the policy change means, what's actually legal now, and how to get compliant metabolic care.

A Meto peptide telehealth comparison showing how insurance-first, physician-led care differs from cash-pay platforms like AgelessRx and Hone Health — covering supervision models, out-of-pocket costs, outcome tracking, and which patients benefit most from each approach.

Category 1 category 2 peptides explained: a plain-English guide to what FDA bulk drug substance categories actually mean — which peptides are available, which aren't, and what the 2026 reclassification means for your access to clinician-supervised peptide therapy.

This peptide therapy glossary covers 60 essential terms — from GH secretagogue meaning to peptide half-life explained — across science, delivery, hormones, regulation, and monitoring. The definitive reference for anyone exploring peptide therapy through Meto's clinician-led platform.

Peptides testosterone male hormonal health: discover how growth hormone peptides like CJC-1295 and ipamorelin work alongside testosterone to restore energy, body composition, and metabolic function.

Kisspeptin male hormone optimization is one of the most evidence-backed frontiers in men's hormonal health. This deep dive covers how kisspeptin stimulates LH and testosterone, what peer-reviewed research confirms, and who is most likely to benefit from this peptide-based approach.

Mitochondrial peptides and insulin resistance are directly linked. MOTS-c, humanin, and SHLP2 activate AMPK, restore GLUT4 glucose transport, and repair cellular energy metabolism — targeting the root cause of type 2 diabetes risk, not just the symptoms.

The PCAC peptide review 2026 is the most consequential regulatory event for compounded peptide therapy. On July 23–24, the FDA's advisory panel will formally evaluate BPC-157 and TB-500 for 503A Bulks List inclusion. This deep dive explains the regulatory timeline, what FDA is actually reviewing, what Thymosin Alpha-1's separate PCAC history means, and how each possible outcome affects your care.

The gray market peptide vs legal compounded 2026 landscape has shifted dramatically. This guide breaks down exactly what gray market peptides are, why research peptide risks are higher than most users realize, how to get legal peptides through a licensed compounding pharmacy, and what compounding pharmacy peptide safety standards actually require — so you can access therapy safely.

Growth hormone peptide therapy labs are the non-negotiable first step before starting any GH secretagogue protocol. This guide covers every baseline test to order — IGF-1, fasting insulin, HbA1c, liver enzymes, thyroid, and more — explains what each result reveals about your GH axis, and shows what your clinician is looking for before prescribing CJC-1295, ipamorelin, tesamorelin, or sermorelin.

PT-141 (bremelanotide) is the only FDA-approved non-hormonal peptide for female sexual desire disorder. This deep dive covers the melanocortin mechanism, RECONNECT Phase 3 trial data, how hormonal conditions like PMOS and perimenopause intersect with low libido, who qualifies for treatment, and what the safety profile actually shows.

Peptides for metabolic syndrome aren't a single solution — they're a category of targeted therapies, each acting on a different biological pathway. This deep dive covers the clinical evidence behind GLP-1 receptor agonists, tesamorelin, and how the PMOS rename (formerly PCOS) changes the treatment framework for women. Includes a selection framework, comparison table, and expert guidance on monitoring.

If you are on semaglutide, tirzepatide, or any GLP-1 receptor agonist and you have spent time in health forums recently, you have almost certainly encountered the acronym KLOW. Peptide stacks are one of the fastest-growing conversations among patients optimising their weight loss journey — and KLOW sits at the centre of that discussion...

Here is what the rename from PCOS to PMOS means, why it matters more than a single letter, and how peptide-based therapies — particularly GLP-1 receptor agonists and kisspeptin — are now supported by growing clinical evidence for the underlying biology of this condition.

BPC-157 gut health research reveals a 15-amino-acid peptide derived from gastric juice that repairs the intestinal lining, counteracts leaky gut syndrome, reduces inflammatory cytokines, and protects against NSAID-induced gut damage. This deep dive covers the mechanisms, evidence, and what it means for patients.

This peptide therapy side effects FAQ explains common risks, medication interactions, long-term safety concerns, and who should not take peptides. Learn which peptide therapies are well-studied, which carry higher risks, and what medical monitoring should happen before treatment begins.